Medrol®
(methylprednisolone tablets)

For Oral Use in Dogs and Cats

DESCRIPTION
Methylprednisolone, a potent anti-inflammatory and immunosuppressive agent, is derived from the Research Laboratories of the Upjohn Company. It is methyl-prednisolone acetate. It is a highly potent anti-inflammatory and immunosuppressive agent. It is available as tablets, each containing 4 mg methylprednisolone.

INDICATIONS
The indications for MEDROL Tablets are the same as for methylprednisolone acetate and other corticosteroids. It is used to control acute inflammation and to suppress inflammatory manifestations, such as those occurring in allergic conditions, such as non-specific asthma, chronic bronchitis, hay fever, allergic rhinitis, urticaria, atopic dermatitis, and urticaria. It may also be used to control chronic inflammatory conditions, such as lupus erythematosus, rheumatoid arthritis, osteoarthritis, and undulant fever. Various chronic or recurrent diseases of unknown etiology such as pemphigus, psoriasis, and dermatitis herpetiformis may be controlled by methylprednisolone acetate. Its advantage over the older corticosteroids is its rapidity of action, relative lack of sodium retaining activity, and its ability to achieve equal anti-inflammatory effect with lower dose, utilized at the same time as enhancing the spasmolytic and anti-inflammatory activities.

CONTRAINDICATIONS
MEDROL Tablets may produce adrenal suppression in patients such as those suffering from diabetes mellitus, use of methylprednisolone, or when the anticipated duration of steroid therapy is of longer than one week. Because the relation of certain disease states to the occurrence of adrenal suppression is not wholly understood, any patient, the conditions of which are adequately controlled by corticosteroids, should be carefully watched when the dose is reduced. Adrenal suppression, due to primary or secondary disease, may be either acute or chronic. Acute adrenal suppression, whether primary or secondary, is primarily manifested by adrenal crisis. In chronic adrenal suppression, the patient may manifest signs and symptoms of hypoadrenalinism, such as excessive fatigue, malaise, weakness, and weight loss. Since methylprednisolone is highly potent, it is capable of producing suppression of the adrenals, even at maintenance levels. Hence, the veterinarian should endeavor to keep informed of patients receiving MEDROL Tablets or hydrocortisone overdosage (ie, increase in body weight, weight gain, and water retention). Its advantage over the older corticosteroids is its rapidity of action, relative lack of sodium retaining activity, and its ability to achieve equal anti-inflammatory effect with lower dose, utilized at the same time as enhancing the spasmolytic and anti-inflammatory activities.

DOSAGE AND ADMINISTRATION
The indications for MEDROL Tablets are the same as for methylprednisolone acetate and other corticosteroids. It is used to control acute inflammation and to suppress inflammatory manifestations, such as those occurring in allergic conditions, such as non-specific asthma, chronic bronchitis, hay fever, allergic rhinitis, urticaria, atopic dermatitis, and urticaria. It may also be used to control chronic inflammatory conditions, such as lupus erythematosus, rheumatoid arthritis, osteoarthritis, and undulant fever. Various chronic or recurrent diseases of unknown etiology such as pemphigus, psoriasis, and dermatitis herpetiformis may be controlled by methylprednisolone acetate. Its advantage over the older corticosteroids is its rapidity of action, relative lack of sodium retaining activity, and its ability to achieve equal anti-inflammatory effect with lower dose, utilized at the same time as enhancing the spasmolytic and anti-inflammatory activities.

WARNING
For use under veterinary supervision only.

PRECAUTIONS
Because of the inhibitory effect on fibroplasia, methylprednisolone may mask the signs of phocomelia, and anasarca.

ADVERSE REACTIONS
With therapeutic improvement doses, the likelihood of occurrence of undesirable side effects is less with methylprednisolone acetate than with prednisolone. Adverse effects may occur with any corticosteroid and vary from mild to severe, from rare to frequent. Changes in appetite, weight gain, or water retention may be noted in animals treated with corticosteroids. Malaise, depression, vomiting, diarrhea, nausea, anorexia, anaphylactic, and hypocalcemic reactions may also occur. With administration of corticosteroids of the glucocorticoid type, increased susceptibility to infection may occur. Adrenocortical suppression may occur with the chronic use of corticosteroids. These effects may occur with methylprednisolone acetate, but are more commonly associated with potent glucocorticoids. Adrenal suppression, due to primary or secondary disease, may be either acute or chronic. Acute adrenal suppression, whether primary or secondary, is primarily manifested by adrenal crisis. In chronic adrenal suppression, the patient may manifest signs and symptoms of hypoadrenalinism, such as excessive fatigue, malaise, weakness, and weight loss.

PHARMACOLOGICAL ACTIONS
Methylprednisolone acetate has a relative lack of mineralocorticoid activity, is highly potent, and has an anti-inflammatory effect. The onset of palliative effects is within 30 minutes. The duration of action lasts at least 24 hours. Its advantage over the older corticosteroids is its rapidity of action, relative lack of sodium retaining activity, and its ability to achieve equal anti-inflammatory effect with lower dose, utilized at the same time as enhancing the spasmolytic and anti-inflammatory activities. Since methylprednisolone, like prednisolone,
suppresses endogenous adrenocortical activity, it is highly important that the animal patient receiving methylprednisolone acetate be under close medical supervision. The dose must be adjusted, if necessary, to avoid suppression of endogenous adrenocortical activity.

STABILITY
The tablets should be stored at controlled room temperature 20° to 25°C (68° to 77°F).

PATIENT INFORMATION
This product is for veterinary use only. It is not for human use. It is furnished in unit dose packages. It is supplied in bottles of 100 tablets. The tablets should be stored at controlled room temperature, 20° to 25°C (68° to 77°F).

SUGGESTED DOSAGE
For Oral Use in Dogs and Cats

Age of Animal

Body Weight

Average Total Daily Oral Dose

15 to 40 lb body wt

2 to 4 mg

40 to 80 lb body wt

4 to 8 mg

80 lb and over

6 to 8 mg

The total daily dose should be given in divided doses, 4 to 8 times each day.

How supplied

MEDROL Tablets are compressed-scored tablets available in bottles of 100. Each tablet contains 4 mg methylprednisolone acetate.

zgetis

Distributed by:

Zoetis Inc.

Wallingford, CT 06492

Revised: September 2019

PA934928